Generics In Europe: Search For Greener Pastures?
Executive Summary
As global market conditions change and companies seek to fill gaps in their service model to payers and patients, are the business interests of originator and generic firms moving closer toward alignment? Surprisingly, the answer may be yes, according to Medicines for Europe director-general Adrian van den Hoven.
You may also be interested in...
EU Generic Industry Group Looks At Radical Options To Simplify Pharmacovigilance Tasks
From looking at ways to reduce the number of audits undertaken by companies to fulfil their pharmacovigilance obligations to calling for harmonized assessment of risk management plans, the EU generics and biosimilars industry group Medicines for Europe says it is ready to explore some radical proposals to simplify the current pharmacovigilance requirements.
Academia Meets The Market – Part Two
New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside.
Academia Meets The Market – Part One
New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside. Its commercial impact is considerable: over the past two decades, private-sector VC’s have invested more than $2bn in UCLA-backed innovations, with 26 start-ups launched through the university in 2019 alone. Amir Naiberg, UCLA’s point man on technology transfer, explains the factors that have made the university a successful advocate for partnerships that produce results for patients.
Need a specific report? 1000+ reports available
Buy Reports